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lacking.We have developed an in-vivomodel to assess specificity and
efficacy of CMV-CTL and establish TC doses required for treat-
ment using colon carcinoma cells transduced with CMVpp65 as
a surrogate system. HLA A02011 human colon carcinoma cells
transduced with CMVpp65 and GFP-firefly luciferase (CoCa-
pp65) were injected subcutaneously (s.c.) into NOD/Scid-IL2Rgc-
KO/J mice (NSG) at doses ranging from 104–106 (4 mice /group)
and tumor growth followed for 4 weeks using bio-luminescent imag-
ing and tumor measurements. Consistent engraftment was observed
with 3  105 cells. Groups of NSG mice were then injected s.c with
CoCa-pp65 (3  105) mixed with HLA A0201-restricted CMV-
CTL (A2-CMV-CTLs) at E:T ratios of 50:1, 10:1, 2:1 and 0.4:1.
To ascertain antigen specificity of A2-CMV-CTLs, groups of 4
NSG mice were subsequently co-injected s.c. with 3 tumor-TC
combinations (E:T 5 1:1) as follows: (i) A2-CMV- CTLs 1 3 
105 CoCa-pp65 (ii) A2-CMV- CTLs 1 A2 tumor without
CMVpp65 (iii) A2-Flu-CTLs 1 3  105 CoCa-pp65. Control ani-
mals were injected with the 2 tumors without TC. IL-2 (2000 U
i.p) was given 2  a week, growth followed by imaging x 4 weeks.
No growth of CoCa-pp65 was detected in any animal co-injected
with A2-CMV-CTL at any E:T ratio, with consistent tumor growth
over 4 weeks in controls. Current experiments are assessing E:T ra-
tios lower than 0.4:1. Tumor growth was observed in control groups
(ii) and (iii) with no detectable growth in (i) by imaging or examina-
tion of autopsied tissues. These studies demonstrate that CMV-
CTL can eradicate clonogenic tumor cells expressing an immuno-
genic viral antigen in-vivo at E:T ratios that are significantly lower
than those required in-vitro. This model also allows for comparison
of cytotoxic activity of TC directed against different immunogenic
epitopes and permits comparisons of virus-specific and tumor spe-
cific TC for their immunotherapeutic potential.374
OVERCOMING ANTIGENIC COMPETITION TO PRODUCE MULTISPECIFIC
CYTOTOXIC T LYMPHOCYTE LINES FOR ADOPTIVE TRANSFER
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HSCT recipients are susceptible to lethal opportunistic infec-
tions, which are often not amenable to conventional therapies. We
have shown that adoptive transfer of just 2  105/kg in vitro ex-
pandedmultivirus-specific cytotoxic T lymphocyte lines (CTLs) tar-
geting EBV, CMV, and Adv can protect against these infections.
Within eachCTL line, however, Adv-specificT cells were aminority
of the total. Furthermore, epitope analysis showed a small number of
Adv epitopes recognized by the trivirus lines, potentially limiting
their antiviral potency. This low frequency and restricted epitope
recognition is likely due to antigen/epitope competition and we
have now devised a means to overcome the problem so that we can
extend the approach to produce CTLs targeting additional viral
pathogens. We proposed that antigenic competition could be over-
come by promoting the survival of T cells with subdominant speci-
ficities using IL-4 and IL-7. Co-culture in the presence of these
cytokines individually or in combination increased total T cell ex-
pansion by 2–6 fold. Further, within 9 days of culture, cytokine-sup-
plemented CTLs had enhanced reactivity (measured by IFNg
ELIspot) against multiple immunodominant and subdominant viral
epitopes from EBV, CMV, and Adv. For example, Adv specificity in
the trivirus CTL detected responses against 5.25 hexon-peptide
pools (range 4–12) vs 1.5 pools (range 0–4) in ‘‘standard’’ CTL
from the same donors (n 5 6). Reactivity to CMV-pp65 was also
broader (10 pools (range 8–15) vs 4 (range 4–5). Anti-viral specific-
ities were sustained over multiple rounds of in vitro stimulation,
and the CTLs were cytolytic in chromium release and co-culture as-
says. In contrast, standard CTLs were only cytolytic against immu-
nodominant antigens. To date, addition of these cytokines has
allowed us to produce single cell lines containing effector cells spe-
cific for multiple epitopes in EBV, CMV, Adv, and BK antigens.
This technology will allow us to produce a single T cell product
which can safely protect against a wide range of pathogens simulta-
neously.375
EXPANSION OF REGULATORY T CELLS WITH ULTRA LOW-DOSE IL-2
AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
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CD41 CD251 FoxP31 regulatory T cells (Tregs) are of increas-
ing interest in hematopoietic stem cell transplantation (HSCT)
since they may help prevent graft-versus-host disease (GvHD). Mu-
rine models demonstrate that infusion of donor-derived Tregs to
HSCT recipient mice can prevent GvHD by suppressing alloreac-
tive T cell responses, while human recipients of allografts with low
Treg numbers have increased rates of GvHD. We and others have
previously given low-dose IL-2 to HSCT recipients in an attempt
to enhance antitumor immunity. Although no definitive antitumor
effects were observed, the patients were noted to have low rates of
GvHD. Retrospectively, it has been demonstrated that patients who
received IL-2 therapy had higher levels of FoxP31 T cells (i.e.,
Tregs) than controls, suggesting that IL-2 preferentially expands
Tregs in vivo, thereby preventing GvHD. We have therefore initi-
ated a phase I/II clinical trial to evaluate the efficacy and toxicity of
low-dose IL-2 injections following allogeneic HSCT. The intent is
to promote Treg expansion in vivo and prevent acute GvHD. Thus
far, 5 patients who received a HSCT for hematologic malignancies
have been treated with ultra low-dose IL-2 (100,000 to 200,000
units/m2 subcutaneously three times weekly) beginning day 17 to
day 128 after HSCT, for 6 to 12 weeks. Median age at time of
transplant was 21 years (range, 9 to 56 years). Two patients received
matched sibling donor transplants and three received alternative
donor transplants with Campath 1-H for in vivo T-cell depletion.
Flow cytometric analysis of blood from all patients demonstrated
a rise in the percentage of CD41 CD251 FoxP31 Tregs by 6 weeks
following initiation of IL-2 therapy with mean of 4.7% (range, 0 to
9.8%) pre IL-2 to a mean of 17.7% (range, 7.8 to 31.1%) after IL-2
treatment. Functional analyses of these CD41 CD25bright cells
showed suppression of thymidine uptake in mixed lymphocyte cul-
tures. No grade 3 or 4 toxicities occurred while on IL-2. No patient
developed . grade I acute GvHD. One patient who did not com-
plete the full 12 weeks of IL-2 therapy developed extensive, chronic
GvHD two months after stopping IL-2. In conclusion, low-dose
IL-2 is relatively well tolerated and may expand a CD41 CD251
FoxP31 Treg population in vivo. Their effects on GvHD and re-
lapse remain to be determined.376
RECOVERY OF IMMUNE CELL SUBSETS POSTTRANSPLANT IS ASSOCI-
ATED WITH INFECTION RISK BUT NOT SURVIVAL, RELAPSE OR NON-
RELAPSE MORTALITY
Geddes, M.1, Barry, S.2, Michael, B.2, Storek, J.1 1University of Calgary,
Calgary, AB, Canada; 2Fred Hutchinson Cancer Center, Seattle, WA
Background: Late recovery of total lymphocyte, CD4 T cell,
CD8 T cell, B cell or monocyte counts post transplant has been as-
sociated with poor transplant outcomes, including infections, in
some but not all studies involving relatively small numbers of pa-
tients. We set out to determine whether transplant outcomes could
be predicted from immune cell subset counts in a relatively large
group of patients (n 5 98) with long follow up (4 1⁄2 years).
Methods: In recipients of matched sibling myeloablative trans-
plant performed in 1996–2000 we prospectively measured the fol-
lowing immune subsets at day 30, 80, 180 and 365: total B cells,
IgD1 (naive) B cells, IgD- (memory) B cells, CD41 T cells,
CD81 T cells, CD41CD81 cells, CD4-CD8- T cells, CD281
(costimulation-competent) or CD28- CD4 or CD8 T cells, naı¨ve
(CD45RAhigh) or memory (CD45RAlow/neg) CD4 T cells, naı¨ve
(CD11alow) or memory (CD11ahigh) CD8 T cells, NK cells and
monocytes. Outcomes determined from a retrospective chart review
included total, definite (microbiologically documented), bacterial,
fungal, viral, HSV, VZV, and CMV infections in the intervals of
days 30–80, 81–180, 181–365, and .365 post transplant, as well as
overall survival, relapse, non-relapse mortality and fatal infection.
